• Witchel HJ (2007) The HERG potassium channel as therapeutic target. Expert. Opin. Ther. Targets. 11 (3): 321-36.
• Tseng GN, Sonawane KD, Zhang M, Liu J, Guy HR (2007) Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling. Biophys. J. (February 9): Ahead of print.
• Phartiyal P, Jones EM, Robertson GA (2007) Heteromeric assembly of hERG 1A/1B channels occurs cotranslationally via amino-terminal interactions. J. Biol. Chem. (February 1): Ahead of print.
• Yi H, Cao Z, Yin S, Dai C, Wu Y, Li W (2007) Interaction Simulation of hERG K(+) Channel with Its Specific BeKm-1 Peptide: Insights into the Selectivity of Molecular Recognition. J. Proteome. Res. 6 (2): 611-20.

Notice: The top ranked publication list is continuously updated. New citations are added regularly.

Abriel H, Schläpfer J, Keller DI, Gavillet B, Buclin T, Biollaz J, Stoller R, Kappenberger L (2004)
Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss Med. Wkly. 134: 685–694.

Cavero I, Mestre M, Guillon JM, Crumb W (2000) Drugs that prolong QT intervals as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac disrhythmias. Expert Opinion on Pharmacotherapy 1: 947-973.

Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM (1998) Molecular determinants of dofetilide block of HERG K+ channels. Circulation Research 82: 386-395.

Kiehn J, Lacerda AE, Wible B, Brown AM (1996) Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 94: 2572-2579.

Mitcheson JS, Chen J, Sanguinetti MC (2000a) Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol 115: 229-239.

Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000b) A structural basis for drug-induced long QT syndrome. PNAS 97: 12329-12333.

Mohammad S, Zhou Z, Gong Q, January CT (1997) Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. American Journal of Physiology 273: H2534-H2538.

Moss AJ, Zareba W, Kaufman ES, Gartman E, Peterson DR, Benhorin J, Towbin JA, Keating MT, Priori SG, Schwartz PJ, Vincent GM, Robinson JL, Andrews ML, Feng C, Hall WJ, Medina A, Zhang L, Wang, Z (2002) Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-go–Related Gene Potassium Channel. Circulation 105: 794-799.

Roden DM and George AL (1997) Structure and function of cardiac sodium and potassium channels. Am. J. Physiol. 273: H511-H525.

Smith PL, Baukrowitz T and Yellen G (1996) The inward rectification mechanism of the HERG cardiac potassium channel. Nature: 379: 833-836.

Shi W, Wymore RS, Wang HS, Pan Z, Cohen IS, McKinnon D (1997) Identification of two nervous system-specific members of the erg potassium channel gene family. Journal of Neuroscience 17: 9423-9432.

Tseng GN (2001) IKr: The hERG channel. J. Mol. Cell Cardiol. 33: 835-849.

Vandenberg JI, Walker BD, Campbell TJ (2001) HERG K+ channels: friend and foe. TIPS 22: 240-246.

Waring MJ, Johnstone C (2006) A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett. (December 22): Ahead of print.

Warmke W and Genetzky B (1994) A family of potassium channel genes related to eag in Drosophila and mammals. PNAS 91: 3438-3442.

Witchel HJ (2007) The HERG potassium channel as therapeutic target. Expert. Opin. Ther. Targets. 11 (3): 321-36.

Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT (1997) Electrophysiological and pharmacological properties of HERG channels in a stably transfected human cell line. Biophysical Journal 72: A225.

Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT (1998) Properties of HERG channels stably expressed in HEK cells studied at physiological temperature. Biophysical Journal 74: 230-241.